



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/21/2016
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/18/2021
ARCHIVE DATE:

LONSURF® (trifluridine-tipiracil) oral tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

LONSURF® (trifluridine-tipiracil) oral tablet

Criteria:

- **Criteria for initial therapy:** Lonsurf (trifluridine-tipiracil) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - a. Metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy
 - b. Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
 - c. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. Individual has failure, contraindication or intolerance to all available regimens **except** regorafenib or trifluridine-tipiracil, previous chemotherapy regimens may include:
 - a. Fluoropyrimidine-, Oxaliplatin-, Irinotecan-based chemotherapy regimen
 - b. Anti-VEGF biological therapy – such as bevacizumab (Avastin) or ramucirumab (Cymraza) or ziv-aflibercept (Zaltrap)
 - c. If has RAS wild-type (is negative for the RAS mutation), an anti-EGFR therapy – such as cetuximab (Erbix) or panitumumab (Vectibix)
 5. **ALL** of the following baseline tests have been completed before initiation of treatment:
 - a. Absolute neutrophil count is $\geq 1,500/\text{mm}^3$
 - b. Platelet count $\geq 75,000/\text{mm}^3$

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Lonsurf (trifluridine-tipiracil) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
 2. Individual's condition has not worsened while on therapy
 - a. Worsening is defined as:
 - i. Cancer progression



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/21/2016
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/18/2021
ARCHIVE DATE:

LONSURF® (trifluridine-tipiracil) oral tablet

3. Individual has been adherent with the medication
4. Individual has not developed any significant level 4 adverse drug effects that may exclude continued use
 - a. Significant adverse effect such as:
 - i. Myelosuppression

Renewal duration: 12 months

Description:

Lonsurf is a combination of trifluridine, a thymidine nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. It is indicated for the treatment of metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Lonsurf is also indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Following Lonsurf uptake into cancer cells, trifluridine is incorporated into DNA, thereby interfering with DNA synthesis and inhibiting cell proliferation. Inclusion of tipiracil results in increased levels of trifluridine by inhibiting its metabolism by thymidine phosphorylase.

Colorectal cancer:

- CRC is the second leading cause of cancer-related death in the US
 - Metastatic CRC (mCRC) accounts for approximately 20% of all CRC diagnoses, and has an estimated 5-year survival rate of 11.9%
 - Survival of patients with mCRC can vary based on certain factors (such as RAS or BRAF mutations)
 - About 35-45% of colorectal cancers have a mutated RAS oncogene, which is strong predictor that the cancer will not respond to EGFR inhibitors
 - The National Comprehensive Cancer Network (NCCN) Colon Cancer and Rectal Cancer guidelines recommend one of five chemotherapy regimens for initial treatment, which contain various combinations of 5-fluorouracil, leucovorin, oxaliplatin, irinotecan and capecitabine
 - Targeted biologic medications [such as Avastin (bevacizumab), Erbitux (cetuximab), or Vectibix (panitumumab)] may also be used as part of initial treatment
 - Treatment for progressive disease varies based on the choice of prior therapy, but options may include Zaltrap (ziv-aflibercept), Cyramza (ramucirumab), Stivarga (regorafenib), Lonsurf (trifluridine/tipiracil), best supportive care, or enrollment in a clinical trial
-



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/21/2016
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/18/2021
ARCHIVE DATE:

LONSURF® (trifluridine-tipiracil) oral tablet

Definitions:

Ant- epidermal growth factor receptor (anti-EGFR)

Erbix (cetuximab)
Vectibix (panitumumab)

Anti-vascular endothelial growth factor (anti-VEGF):

Avastin (bevacizumab)
Cyramza (ramucirumab)
Stivarga (regorafenib)
Zaltrap (ziv-aflibercept)

Platinum coordination complex:

Eloxatin (oxaliplatin, generics available)

Pyrimidines

Fluorouracil
Lonsurf (trifluridine/tipiracil)
Xeloda (capecitabine, generics available)

Topoisomerase inhibitors:

Camptosar (irinotecan, generics available)

Taxanes

Docetaxel

Resources:

Lonsurf (trifluridine and tipiracil) product information, revised by Taiho Pharmaceutical Co., Ltd. 12-2019, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed January 30, 2021.

Lonsurf (trifluridine and tipiracil). National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium. 2021; Available at: <http://www.nccn.org>. Accessed January 30, 2021.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.
